The Clinical Role of miRNAs in the Development and Treatment of Glioblastoma

Glioblastoma multiforme (GBM) is the most common brain tumor and one of the most aggressive, with a median overall survival (OS) of only 15–18 months. These characteristics make it necessary to identify new targets for the improvement of prognosis and better prediction of response to therapies curre...

Full description

Saved in:
Bibliographic Details
Published inInternational journal of molecular sciences Vol. 26; no. 6; p. 2723
Main Authors Epistolio, Samantha, Spina, Paolo, Zaed, Ismail, Cardia, Andrea, Marchi, Francesco, Frattini, Milo
Format Journal Article
LanguageEnglish
Published Switzerland MDPI AG 18.03.2025
MDPI
Subjects
Adults
Animals
Biomarkers, Tumor - genetics
Brain cancer
Brain Neoplasms - genetics
Brain Neoplasms - pathology
Brain Neoplasms - therapy
Brain research
Brain tumors
Cancer therapies
Classification
Clinical outcomes
Clinical trials
DNA methylation
Gene amplification
Gene Expression Regulation, Neoplastic
Genes
Genetic transcription
Genomes
Glioblastoma - genetics
Glioblastoma - pathology
Glioblastoma - therapy
Glioblastoma multiforme
Glioma
Humans
Medical prognosis
MicroRNA
MicroRNAs - genetics
MicroRNAs - metabolism
Mutation
Patients
Pediatrics
Prognosis
Radiation therapy
Review
Tumors
TMZ
treatment
GBM
miRNAs
prognosis
survival
Online AccessGet full text

Cover

More Information
Summary:Glioblastoma multiforme (GBM) is the most common brain tumor and one of the most aggressive, with a median overall survival (OS) of only 15–18 months. These characteristics make it necessary to identify new targets for the improvement of prognosis and better prediction of response to therapies currently available for GBM patients. One possible candidate target could be the evaluation of miRNAs. miRNAs are small non-coding RNAs that play important roles in post-transcriptional gene regulation. Due to their functions, miRNAs also control biological processes underlying the development of GBM and may be considered possible targets with a clinical role. This narrative review introduces the concept of miRNAs in GBM from a clinical and a molecular perspective and then addresses the specific miRNAs that are most described in the literature as relevant for the development, the prognosis, and the response to therapies for patients affected by GBM.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ObjectType-Review-3
content type line 23
These authors share co-first authorship.
These authors share co-last authorship.
ISSN:1422-0067
1661-6596
1422-0067
DOI:10.3390/ijms26062723